RhumbLine Advisers’s Olema Pharmaceuticals OLMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $366K | Buy |
86,027
+27,972
| +48% | +$119K | ﹤0.01% | 2873 |
|
|
2025
Q1 | $218K | Sell |
58,055
-378
| -0.6% | -$1.42K | ﹤0.01% | 3062 |
|
|
2024
Q4 | $341K | Buy |
58,433
+572
| +1% | +$3.34K | ﹤0.01% | 2911 |
|
|
2024
Q3 | $691K | Sell |
57,861
-1,400
| -2% | -$16.7K | ﹤0.01% | 2490 |
|
|
2024
Q2 | $641K | Buy |
59,261
+17,953
| +43% | +$194K | ﹤0.01% | 2493 |
|
|
2024
Q1 | $468K | Buy |
41,308
+1,132
| +3% | +$12.8K | ﹤0.01% | 2702 |
|
|
2023
Q4 | $564K | Buy |
40,176
+2,336
| +6% | +$32.8K | ﹤0.01% | 2591 |
|
|
2023
Q3 | $467K | Buy |
37,840
+4,787
| +14% | +$59.1K | ﹤0.01% | 2650 |
|
|
2023
Q2 | $298K | Buy |
+33,053
| New | +$298K | ﹤0.01% | 3023 |
|
|
2022
Q2 | – | Sell |
-28,682
| Closed | -$122K | – | 3194 |
|
|
2022
Q1 | $122K | Buy |
28,682
+2,335
| +9% | +$9.93K | ﹤0.01% | 2850 |
|
|
2021
Q4 | $247K | Sell |
26,347
-160
| -0.6% | -$1.5K | ﹤0.01% | 2770 |
|
|
2021
Q3 | $731K | Buy |
26,507
+13,373
| +102% | +$369K | ﹤0.01% | 2372 |
|
|
2021
Q2 | $367K | Buy |
13,134
+2,168
| +20% | +$60.6K | ﹤0.01% | 2704 |
|
|
2021
Q1 | $364K | Buy |
+10,966
| New | +$364K | ﹤0.01% | 2630 |
|